Dr. Daglish successfully defended her PhD thesis, “Small Molecule ClpP Activators Impair Mitochondrial Function and Induce Senescence in Triple-Negative Breast Cancer” under the direction of Dr. Lee Graves!
Dr. Daglish will be moving to the Bay area to start a postdoctoral fellowship position with Gilead Sciences.
Publications
Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax. Daglish SCD, Canterbury OG, Graves PR, Carter SA, Beese SM, Hynek MA, Mouery BL, Mistreanu AJ, Bhatt AP, Tellez N, Butler MT, Aponte-Collazo LJ, Fennell EMJ, Herring LE, Lyons S, Mills CA, Ashamalla H, Iwanowicz EJ, Morris JP 4th, Bear JE, Greer YE, Lipkowitz S, Graves LM. Res Sq [Preprint]. 2025 Nov 19:rs.3.rs-7682325. doi: 10.21203/rs.3.rs-7682325/v1. PMID: 41333384. PMC13089524
Development of SYK NanoBRET cellular target engagement assays for gain-of-function variants. Capener JL, Vasta JD, Katis VL, Michaud A, Beck MT, Daglish SCD, Cohen-Kedar S, Barda ES, Howell S, Dotan I, Robers MB, Axtman AD, Bashore FM. Front Chem Biol. 2024;3:10.3389/fchbi.2024.1447622. doi: 10.3389/fchbi.2024.1447622. Epub 2024 Jul 28. PMID: 42004161 PMC13089524
Combining the constitutive TRAIL-secreting induced neural stem cell therapy with the novel anti-cancer drug TR-107 in glioblastoma. Thang M, Mellows C, Kass LE, Daglish S, Fennell EMJ, Mann BE, Mercer-Smith AR, Valdivia A, Graves LM, Hingtgen SD. Mol Ther Oncol. 2024 Jun 15;32(3):200834. doi: 10.1016/j.omton.2024.200834. eCollection 2024 Sep 19. PMID: 39045029. PMC11263637.
Targeting Mitochondrial DNA Transcription by POLRMT Inhibition or Depletion as a Potential Strategy for Cancer Treatment. Daglish SCD, Fennell EMJ, Graves LM. Biomedicines. 2023 May 31;11(6):1598. doi: 10.3390/biomedicines11061598. PMID: 37371693 PMC10295849
Honors, Awards & Highlights
Best Poster Presentation Award, Pharmacology Research Retreat 2025
We wish you all the best, Sabrina!